Charles Schwab Investment Management Inc. raised its stake in Teladoc Health, Inc. (NYSE:TDOC - Free Report) by 5.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,571,673 shares of the health services provider's stock after purchasing an additional 127,960 shares during the period. Charles Schwab Investment Management Inc. owned 1.47% of Teladoc Health worth $20,471,000 as of its most recent SEC filing.
Several other institutional investors have also modified their holdings of TDOC. Point72 Asset Management L.P. grew its position in shares of Teladoc Health by 33.6% in the 4th quarter. Point72 Asset Management L.P. now owns 11,179,863 shares of the health services provider's stock valued at $101,625,000 after buying an additional 2,813,568 shares during the last quarter. Maple Rock Capital Partners Inc. grew its holdings in shares of Teladoc Health by 189.5% during the fourth quarter. Maple Rock Capital Partners Inc. now owns 3,561,000 shares of the health services provider's stock worth $32,369,000 after purchasing an additional 2,331,000 shares during the last quarter. Two Sigma Investments LP purchased a new position in shares of Teladoc Health during the fourth quarter worth about $18,348,000. Two Sigma Advisers LP increased its position in shares of Teladoc Health by 213.0% during the fourth quarter. Two Sigma Advisers LP now owns 2,258,711 shares of the health services provider's stock worth $20,532,000 after purchasing an additional 1,537,094 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Teladoc Health by 7.0% in the 1st quarter. Vanguard Group Inc. now owns 19,752,338 shares of the health services provider's stock valued at $157,229,000 after purchasing an additional 1,289,183 shares during the last quarter. Hedge funds and other institutional investors own 76.82% of the company's stock.
Teladoc Health Stock Performance
Shares of TDOC stock opened at $7.1850 on Friday. The company has a market cap of $1.27 billion, a price-to-earnings ratio of -6.04 and a beta of 1.76. The stock has a 50 day simple moving average of $7.72 and a 200-day simple moving average of $8.24. Teladoc Health, Inc. has a 12-month low of $6.35 and a 12-month high of $15.21. The company has a current ratio of 2.67, a quick ratio of 2.58 and a debt-to-equity ratio of 0.70.
Teladoc Health (NYSE:TDOC - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The health services provider reported ($0.19) earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.08. The firm had revenue of $631.90 million for the quarter, compared to the consensus estimate of $621.91 million. Teladoc Health had a negative return on equity of 10.13% and a negative net margin of 8.16%.The company's revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.38) earnings per share. Teladoc Health has set its Q3 2025 guidance at -0.350--0.200 EPS. FY 2025 guidance at -1.350--1.000 EPS. On average, equities analysts forecast that Teladoc Health, Inc. will post -1.16 EPS for the current year.
Analyst Upgrades and Downgrades
A number of equities analysts have recently issued reports on TDOC shares. Evercore ISI raised their target price on shares of Teladoc Health from $7.00 to $8.00 and gave the stock an "in-line" rating in a research report on Wednesday, July 9th. Bank of America decreased their price target on shares of Teladoc Health from $8.00 to $7.00 and set a "neutral" rating for the company in a research note on Wednesday, May 28th. Stifel Nicolaus lowered their price objective on shares of Teladoc Health from $9.00 to $8.00 and set a "hold" rating on the stock in a research report on Thursday, May 1st. Truist Financial reduced their target price on shares of Teladoc Health from $10.00 to $9.00 and set a "hold" rating for the company in a report on Tuesday, May 27th. Finally, Canaccord Genuity Group decreased their target price on shares of Teladoc Health from $14.00 to $12.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. Six analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the stock. According to MarketBeat.com, Teladoc Health currently has a consensus rating of "Hold" and an average target price of $9.75.
Check Out Our Latest Report on Teladoc Health
Insider Buying and Selling at Teladoc Health
In related news, insider Fernando M. Rodrigues sold 4,174 shares of the firm's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $6.91, for a total value of $28,842.34. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Adam C. Vandervoort sold 5,808 shares of Teladoc Health stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $6.86, for a total value of $39,842.88. Following the transaction, the insider directly owned 69,773 shares of the company's stock, valued at approximately $478,642.78. This represents a 7.68% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 18,656 shares of company stock valued at $128,189. Corporate insiders own 0.58% of the company's stock.
About Teladoc Health
(
Free Report)
Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Teladoc Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teladoc Health wasn't on the list.
While Teladoc Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access